反応式
Cl[C:2]1[C:3](=[O:15])[N:4](C2CCCCO2)[N:5]=[CH:6][C:7]=1Cl.[O:16]1[C:21]2[CH:22]=[CH:23][CH:24]=[C:25]([OH:26])[C:20]=2[O:19][CH2:18][CH2:17]1.C[O:28][C:29](=[O:39])[CH:30](Br)[CH2:31][CH:32]1[CH2:37][CH2:36][CH2:35][CH2:34][CH2:33]1>>[CH:32]1([CH2:31][CH:30]([N:4]2[C:3](=[O:15])[CH:2]=[C:7]([O:26][C:25]3[C:20]4[O:19][CH2:18][CH2:17][O:16][C:21]=4[CH:22]=[CH:23][CH:24]=3)[CH:6]=[N:5]2)[C:29]([OH:28])=[O:39])[CH2:37][CH2:36][CH2:35][CH2:34][CH2:33]1参加物
4
実験手順
In an analogous manner to the stepwise sequence outlined in Intermediate 19, starting from 4,5-dichloro-2-(tetrahydropyran-2-yl)-2H-pyridazin-3-one (Intermediate 20) and 2,3-dihydro-benzo[1,4]dioxin-5-ol and alkylating with 2-bromo-3-cyclohexyl-propionic acid methyl ester (Intermediate 12) afforded 3-cyclohexyl-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-6-oxo-6H-pyridazin-1-yl]-propionic acid (30 mg, 89% for the final step) which was used in Example 133.
出典と根拠
- ORDレコード
- ord-74b14fa0247e4bbaa03e500ba47bbc91
- 出典データセット
- uspto-grants-2012_09
- 特許番号
- US08258134B2
関連ノート
読み込み中…